Citation
Massiot, Philippe, et al. "Continuous Clinical Improvement of Mild-to-moderate Seborrheic Dermatitis and Rebalancing of the Scalp Microbiome Using a Selenium Disulfide-based Shampoo After an Initial Treatment With Ketoconazole." Journal of Cosmetic Dermatology, vol. 21, no. 5, 2022, pp. 2215-2225.
Massiot P, Clavaud C, Thomas M, et al. Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole. J Cosmet Dermatol. 2022;21(5):2215-2225.
Massiot, P., Clavaud, C., Thomas, M., Ott, A., Guéniche, A., Panhard, S., Muller, B., Michelin, C., Kerob, D., Bouloc, A., & Reygagne, P. (2022). Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole. Journal of Cosmetic Dermatology, 21(5), 2215-2225. https://doi.org/10.1111/jocd.14362
Massiot P, et al. Continuous Clinical Improvement of Mild-to-moderate Seborrheic Dermatitis and Rebalancing of the Scalp Microbiome Using a Selenium Disulfide-based Shampoo After an Initial Treatment With Ketoconazole. J Cosmet Dermatol. 2022;21(5):2215-2225. PubMed PMID: 34416081.
TY - JOUR
T1 - Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole.
AU - Massiot,Philippe,
AU - Clavaud,Cécile,
AU - Thomas,Marie,
AU - Ott,Alban,
AU - Guéniche,Audrey,
AU - Panhard,Ségolène,
AU - Muller,Benoît,
AU - Michelin,Céline,
AU - Kerob,Delphine,
AU - Bouloc,Anne,
AU - Reygagne,Pascal,
Y1 - 2021/08/20/
PY - 2021/06/24/revised
PY - 2021/04/07/received
PY - 2021/07/22/accepted
PY - 2021/8/21/pubmed
PY - 2022/5/25/medline
PY - 2021/8/20/entrez
KW - ketoconazole
KW - scalp microbiota
KW - seborrheic dermatitis
KW - selenium disulfide
SP - 2215
EP - 2225
JF - Journal of cosmetic dermatology
JO - J Cosmet Dermatol
VL - 21
IS - 5
N2 - OBJECTIVE: Scalp seborrheic dermatitis (SD) is a chronic, relapsing, and inflammatory scalp disease. Studies indicate a global bacterial and fungal microbiota shift of scalp SD, as compared to healthy scalp. Ketoconazole and selenium disulfide (SeS2) improve clinical signs and symptoms in both scalp dandruff and SD. AIM: The main objective of this study was to investigate the changes in the scalp microbiota diversity and counts in subjects with scalp SD during a two-phase treatment period. MATERIAL AND METHODS: The scalp microbiota and clinical efficacy were investigated in 68 subjects with mild-to-moderate scalp SD after an initial one-month treatment with 2% ketoconazole, and after a 2-month maintenance phase, either with a 1% SeS2 -based shampoo or its vehicle. RESULTS: Thirty one subjects in the active and 37 subjects in the vehicle group participated. Ketoconazole provided an improvement of clinical symptoms (adherent (-1.75 p < 0.05), non-adherent (-1.5, p < 0.05)) flakes and erythema (scores 1.67-0.93, p < 0.001), in an increased fungal diversity and in a significant (p < 0.005) decrease of Malassezia spp. SeS2 provided an additional clinical improvement (-0.8; p = 0.0002 and -0.7; p = 0.0081 for adherent and non-adherent flakes, respectively, at Day 84) compared to the vehicle associated with a low Malassezia spp. count and an additional significant (p < 0.001) decrease of the Staphylococcus spp. level. CONCLUSION: Selenium disulfide provides an additional benefit on the scalp microbiota and in clinical symptoms of SD and dandruff after treatment with ketoconazole. The results confirm the role of Staphylococcus spp. in scalp SD and open possible perspectives for preventing relapses.
SN - 1473-2165
UR - https://www.unboundmedicine.com/medline/citation/34416081/Continuous_clinical_improvement_of_mild_to_moderate_seborrheic_dermatitis_and_rebalancing_of_the_scalp_microbiome_using_a_selenium_disulfide_based_shampoo_after_an_initial_treatment_with_ketoconazole_
DB - PRIME
DP - Unbound Medicine
ER -